Hyperbaric oxygen therapy (HBOT) keeps showing up in ads for erectile dysfunction (ED). The pitch sounds good: pressurized oxygen grows new blood vessels in the penis and fixes the root cause of poor blood flow. But the human evidence is small, mixed, and sometimes funded by the people selling the treatment. This atlas walks through what the angiogenesis trials actually found, where the data are strong, where they fall apart, and how HBOT stacks up against treatments that already work.
The short version of where the science stands
ED has a few main causes. The most common is vasculogenic, meaning the blood vessels that fill the penis are narrowed or damaged. The theory behind HBOT is simple. Breathe 100% oxygen at higher-than-normal pressure, and you flood the blood with oxygen. That oxygen-rich environment can trigger the body to build new tiny blood vessels, a process called angiogenesis. More vessels, better blood flow, better erections.
That mechanism is real and well documented in wound healing. The question is whether it translates into lasting erectile function in men, and whether the effect holds up when you compare HBOT against a fake (placebo) treatment instead of just measuring before and after. That second part is where the story gets complicated. One uncontrolled study showed huge gains. One rigorous placebo-controlled trial showed nothing. The honest answer in 2026 is that HBOT for ED is investigational, not proven.
How HBOT is supposed to work on erections
An erection is a plumbing event. When you get aroused, nerves signal the smooth muscle inside the penis to relax. Blood rushes into two spongy chambers called the corpora cavernosa, the chambers swell, and the swelling pinches off the veins so blood stays trapped. If the arteries feeding those chambers are clogged or stiff, not enough blood gets in, and the erection is weak or fails.
HBOT targets the inflow problem. Inside a hyperbaric chamber, pressure is raised to roughly 2.0 to 2.5 times normal atmospheric pressure (written as ATA), and you breathe pure oxygen. This dissolves far more oxygen into the blood plasma than normal breathing ever could. The high oxygen level does a few things that matter for blood vessels:
- It stimulates growth factors like VEGF (vascular endothelial growth factor) that tell the body to sprout new capillaries.
- It mobilizes stem cells from bone marrow that help build vessel walls.
- It may improve the lining of existing vessels (the endothelium), which controls how well they dilate.
The penile angiogenesis idea was tested directly in one study using a special MRI scan that measures blood vessel leakiness and density. We'll get to that result below. The mechanism is plausible. Plausible is not the same as proven, and this is the gap the trials are meant to close.
Why oxygen at pressure might rebuild blood vessels
Normally, almost all the oxygen you breathe rides on hemoglobin inside red blood cells. Those cells can only carry so much, and they can't squeeze into areas where the blood supply is already poor. HBOT changes that by forcing oxygen to dissolve directly into the watery part of blood, the plasma. Plasma reaches places red cells struggle to go. That's the core trick.
A high-oxygen, high-pressure state sends a strange signal to the body. Tissues briefly behave as if they're being starved and flooded at the same time, which switches on repair pathways. The most studied of these is hypoxia-inducible factor, or HIF, a master switch that turns up genes for building blood vessels. HBOT also raises nitric oxide, the same molecule that ED pills work through, because nitric oxide relaxes the smooth muscle in arteries and lets them open wider.
In wound-healing clinics, this chain of events is well established. Diabetic foot ulcers and radiation-damaged tissue genuinely heal better with HBOT, and that's why those are FDA-cleared uses. The leap of faith with ED is assuming the same vessel-building that helps a foot ulcer will rebuild the deep arteries of the penis enough to restore erections. It might. The wound-healing success is the strongest argument in HBOT's favor. But a foot wound and an erection are different problems, and what helps one doesn't automatically fix the other.
Not all ED is the same
The HBOT theory only makes sense for certain kinds of ED. It's worth knowing which type you have before assuming oxygen could help.
| ED type | Root cause | Could HBOT theory apply? |
|---|---|---|
| Vasculogenic | Narrowed or stiff penile arteries; poor blood inflow | Yes, in theory — this is the target |
| Neurogenic | Nerve damage (e.g., after prostate surgery, diabetes, spinal injury) | Unlikely — HBOT doesn't regrow nerves; the RCT in this group failed |
| Hormonal | Low testosterone | No — needs hormone treatment, not oxygen |
| Psychogenic | Anxiety, depression, relationship stress | No — needs counseling or pills |
| Drug-induced | Side effect of blood pressure meds, antidepressants | No — needs a medication change |
This table explains a lot about the conflicting trial results. The one rigorous placebo-controlled study tested men with nerve damage from prostate surgery, which is mostly neurogenic ED. HBOT wouldn't be expected to help nerve damage, and it didn't. The positive single-arm study enrolled men with chronic, mostly vasculogenic ED, which is where the theory could plausibly work. So the field hasn't actually run the cleanest test yet: a placebo-controlled trial in pure vasculogenic ED. Until someone does, the question stays open.
The actual evidence, study by study
There are only a handful of human studies. Most are small. Only one used a placebo control, which is the gold standard for separating a real drug effect from hope, attention, and the natural ups and downs of ED. Here is the full picture, graded honestly.
| Study (year) | Design | Patients | Protocol | Main result | Evidence quality |
|---|---|---|---|---|---|
| Hadanny et al. 2018 | Single-arm, no control | 30 men, mean age 59, chronic ED | 40 daily sessions, 2 ATA | IIEF domains improved 15–88%; 80% reported benefit on global question; perfusion MRI showed large rise in penile blood flow markers | Low. No placebo group; can't rule out placebo effect |
| Sahin et al. 2018 | Prospective clinical study, no placebo | 30 men | 30 sessions, ~2.4 ATA | IIEF scores rose significantly after treatment | Low. Uncontrolled before/after design |
| Chiles et al. 2018 (J Urol) | Double-blind, randomized, placebo-controlled | Men after nerve-sparing radical prostatectomy | HBOT vs sham (air) in chamber | No difference in erectile recovery vs placebo; HBOT was safe | Moderate-high. The only true RCT; it was negative |
| Eker et al. 2024 | Prospective, three groups (HBOT vs none vs daily tadalafil) | Men with ED getting HBOT for other reasons | ~1 month | Both HBOT and tadalafil raised IIEF-5 scores vs no treatment | Low-moderate. Not placebo-controlled; tadalafil already works |
| Meta-analysis 2023 (Sex Med Rev) | Pooled 5 studies | Mixed | Varied | Pooled effect favored HBOT, especially for vasculogenic ED | Limited by weak source studies; pooling weak data doesn't make it strong |
The study that started the buzz
The most cited paper is the 2018 single-arm trial by Hadanny and colleagues, published in the International Journal of Impotence Research. Thirty men with chronic ED did 40 daily HBOT sessions. Their erectile function scores improved a lot, and perfusion MRI showed a 153% jump in a marker of penile blood flow in the corpora cavernosa. The authors concluded HBOT can induce penile angiogenesis and recover erectile function.
This is the angiogenesis evidence everyone quotes. It's also the weakest kind of trial design. There was no control group. Every man knew he was getting the real treatment. ED scores are subjective and respond strongly to placebo, attention, and the simple act of showing up daily for six weeks. The MRI finding is more objective and genuinely interesting, but 30 men with no comparison group can't prove cause and effect.
The study nobody markets
When researchers ran the rigorous version, the result flipped. The 2018 double-blind randomized trial in the Journal of Urology enrolled men who had nerve-sparing radical prostatectomy, a surgery that frequently causes ED. Men were randomly assigned to real HBOT or a sham chamber session (pressurized air, not oxygen), and nobody knew which they got. Erectile recovery at follow-up was no better with HBOT than with placebo.
That's the single most important data point in this whole field, and it almost never appears in clinic marketing. A proper placebo control erased the benefit. The therapy was safe, but it didn't beat a fake treatment. The authors did note this was a specific population (post-surgery nerve damage) and called for larger studies, so it doesn't close the book on vasculogenic ED from poor blood flow. But it's a serious warning sign.
Why the meta-analysis looks better than the evidence is
A 2023 meta-analysis pooled five studies and reported a favorable effect, especially for pure vasculogenic ED. That sounds reassuring until you remember what went in. Garbage in, garbage out applies to meta-analysis. Pooling several small, mostly uncontrolled before/after studies produces a tidy number with tight-looking confidence intervals, but it inherits all the placebo contamination of the source studies. The one real RCT in the field was negative. A meta-analysis that leans on weak designs can't outrank a single well-run placebo-controlled trial.
How to read the evidence grades
It helps to know why some studies count more than others. Not all "studies" carry the same weight, and the gap between the best and worst designs here is wide.
| Evidence tier | What it means | Where HBOT-for-ED studies sit |
|---|---|---|
| Randomized, double-blind, placebo-controlled | Strongest. Neither patient nor doctor knows who got the real treatment, so hope and bias cancel out | One trial (post-prostatectomy) — it was negative |
| Randomized, not blinded | Decent, but knowing your assignment can bias subjective scores | Partial; comparison studies exist but lack sham control |
| Single-arm before/after | Weak. No comparison group; placebo and natural variation contaminate results | The "88% improvement" angiogenesis study |
| Case reports / clinic testimonials | Weakest. Cherry-picked, no denominator | Most marketing claims |
The pattern in this field is upside down from what you'd want. The strongest study was negative. The weakest studies were positive. When that happens, the honest reading leans toward the strong study, because the whole reason placebo controls exist is that uncontrolled studies routinely overstate benefit. Roughly 30 to 40 percent of men in ED trials improve on placebo alone. That's a huge effect to leave unaccounted for, and the positive HBOT studies didn't account for it.
There's also a simple sample-size problem. Thirty men is a tiny trial. With numbers that small, a few lucky responders can swing the average, and the result may not repeat in a larger group. Real proof in medicine usually requires hundreds of patients across multiple sites. Nothing close to that has been done for HBOT and ED.
A blunt look at the conflicts of interest
Several of the loudest HBOT-for-ED voices are tied to clinics that sell the treatment. The flagship single-arm study comes from a research group closely linked to commercial hyperbaric clinics. That doesn't make the findings fake, but it raises the bar for skepticism. Industry-adjacent, uncontrolled, positive studies are exactly the pattern you'd expect whether or not the treatment works, because there's no placebo group to keep the result honest. When you see a clinic cite an "88% improvement," ask one question: compared to what? In the trial that included a real comparison, the gap vanished.
How HBOT compares to treatments that already work
This is where perspective matters. ED has cheap, proven, well-studied treatments. HBOT is expensive, time-consuming, and unproven. Here's the head-to-head.
| Treatment | How well it works | Evidence level | Typical cost | Burden |
|---|---|---|---|---|
| PDE5 inhibitors (sildenafil, tadalafil) | Works for ~60–70% of men | High; many large RCTs; FDA-approved | $10–40/month generic | One pill as needed or daily |
| Vacuum erection device | Works for many; mechanical | Moderate; long track record | $100–500 one-time | Device use before sex |
| Penile injections (alprostadil) | Works for ~70–80%, even when pills fail | High; FDA-approved | Varies | Self-injection |
| Low-intensity shockwave therapy | Promising for vasculogenic ED; still emerging | Moderate; mixed RCTs | $2,000–4,000/course | In-office series |
| Penile implant (surgery) | Very high satisfaction | High for refractory ED | $15,000–25,000 | Surgery |
| HBOT | Unclear; failed the one placebo RCT | Low; investigational | $4,000–12,000 for 40 sessions | 40 daily clinic visits |
The contrast is stark. A generic tadalafil prescription costs less than a single HBOT session and has decades of high-quality evidence behind it. Major urology guidance, including the American Urological Association's ED guideline, centers on these proven options. HBOT does not appear as a recommended ED treatment in mainstream urology guidelines. If you're exploring ED treatment, the evidence-based ladder starts with pills, then devices or injections, then shockwave or surgery for tough cases. HBOT sits off to the side, still being studied.
The HBOT-versus-tadalafil study, explained
One 2024 study did put HBOT head-to-head with daily tadalafil. Both groups improved their erectile scores over a month, which clinics sometimes spin as "HBOT works as well as Cialis." Read it carefully, though. The study wasn't blinded, the HBOT patients were already in chambers for other medical reasons, and the comparison doesn't prove HBOT caused the gain. It mainly confirms what we already knew: tadalafil works. If anything, the takeaway is that a daily pill you can take at home matched a treatment that requires 40 trips to a clinic. That's an argument for the pill, not the chamber.
The protocol clinics actually use
If you do look into HBOT for ED, here's the typical off-label setup so you know what you'd be signing up for. Note that none of this is standardized or guideline-backed for ED, because no guideline endorses it.
| Protocol element | Typical setting | Notes |
|---|---|---|
| Pressure | 2.0–2.4 ATA | Higher than mild "wellness" chambers (1.3 ATA), which have even less evidence |
| Session length | 60–90 minutes | Plus compression and decompression time |
| Number of sessions | 40 | Mirrors the research protocol |
| Schedule | Once daily, 5 days/week | Roughly 8 weeks of near-daily clinic visits |
| Chamber type | Hard monoplace or multiplace | Medical-grade; mild soft-shell chambers don't reach therapeutic pressure |
The mild, low-pressure "wellness" chambers marketed for home use sit at about 1.3 ATA and dissolve far less oxygen than the 2.0+ ATA used in the actual research. If a clinic claims ED benefits from a soft-shell 1.3 ATA chamber, that's even further from the (already thin) evidence. For more on this distinction, see our breakdown of mild HBOT versus medical HBOT and why 1.3 ATA is controversial.
Who might consider it, and who shouldn't
HBOT for ED is not a first-line option for anyone in 2026. If you're curious about it, the most defensible scenario is a man with vasculogenic ED who has tried and failed standard treatments, who understands the evidence is thin, and who enrolls in a registered clinical trial rather than paying cash at a wellness clinic. Trials are how this question actually gets answered, and you'd be contributing to real data instead of funding marketing.
Men who should steer clear: anyone who hasn't tried proven first-line treatments yet, anyone being told HBOT is a guaranteed cure, and anyone with certain medical conditions that make hyperbaric treatment risky. HBOT has real contraindications, including untreated pneumothorax (collapsed lung) and some lung diseases, and it isn't free of side effects.
Safety: what HBOT can do to you
The good news from the trials is consistency on safety. Even the negative RCT confirmed HBOT was well tolerated. But "tolerated" isn't "harmless." Known risks include:
- Ear and sinus barotrauma. The most common issue. Pressure changes can cause ear pain or damage the eardrum. Equalizing techniques help, but it's frequent.
- Temporary nearsightedness. Vision can shift after repeated sessions and usually reverses over weeks to months.
- Oxygen toxicity seizures. Rare but serious; high oxygen pressure can overstimulate the brain.
- Fire risk. Chambers are oxygen-rich. Sparks are dangerous, which is why clinics ban certain clothing and electronics.
- Claustrophobia. Monoplace chambers are tight, enclosed tubes; some men can't tolerate them.
For a deeper breakdown, see our guide on HBOT side effects, risks and what you need to know and the rundown of contraindications when HBOT is genuinely dangerous.
The regulatory reality
The FDA has cleared hyperbaric chambers for a specific list of medical uses, like decompression sickness, certain non-healing wounds, and carbon monoxide poisoning. Erectile dysfunction is not on that list. The FDA has publicly warned that some centers promote HBOT for unproven uses and that patients may wrongly assume those uses are FDA-approved. Using HBOT for ED is off-label and out-of-pocket. Insurance won't cover it for this purpose. For the full picture of what is and isn't covered, see the 14 approved HBOT indications and insurance coverage and our broader look at what the clinical research says about HBOT.
Putting the cost in perspective
A standard course is 40 sessions. At typical off-label cash prices, that runs several thousand to over ten thousand dollars, with no guarantee of benefit and a negative result from the one rigorous trial. Compare that to a month of generic tadalafil for the price of a couple of coffees. Before spending on HBOT, it's worth reading how HBOT pricing and session packages actually work so you understand what you'd be paying for. The math rarely favors HBOT as a first move for ED.
Bottom line
The angiogenesis mechanism behind HBOT for ED is real biology. The early single-arm trial and its MRI findings are genuinely intriguing. But intriguing isn't proven. The one double-blind, placebo-controlled trial found no benefit over a fake treatment, and that result outweighs a stack of uncontrolled studies, some tied to clinics that profit from the therapy. For now, HBOT for ED is investigational. Proven, affordable treatments should come first. If you want to try HBOT for ED, the right venue is a clinical trial, not a cash-pay wellness clinic.
Frequently Asked Questions
Is HBOT an FDA-approved treatment for erectile dysfunction?
No. The FDA has cleared hyperbaric chambers for a defined list of conditions, and ED is not among them. Using HBOT for ED is off-label, unproven, and not covered by insurance for that purpose.
What did the angiogenesis study actually show?
A 2018 single-arm study of 30 men found big improvements in erectile function scores and a large rise in penile blood flow on MRI after 40 sessions. But it had no control group, so it couldn't separate a real effect from placebo. It's suggestive, not conclusive.
Why do some clinics claim such high success rates?
Most clinic claims come from before-and-after studies with no placebo group. ED scores improve a lot just from attention and expectation. When researchers ran a proper placebo-controlled trial, the benefit disappeared, which is why marketing numbers should be read with caution.
Is HBOT better than ED pills like Viagra or Cialis?
No evidence supports that. PDE5 inhibitors work for most men, are FDA-approved, backed by large trials, and cost a fraction of an HBOT course. HBOT has failed its only rigorous trial. Pills remain first-line.
Is HBOT safe to try for ED?
It's generally well tolerated, but not risk-free. Ear barotrauma, temporary vision changes, rare oxygen seizures, and fire risk are real. It also has contraindications. Given the weak evidence, the safest path is a registered clinical trial under medical supervision.
Medical disclaimer: This article is for general information only and is not medical advice. Talk to a licensed physician before starting or stopping any treatment for erectile dysfunction.
Sources
- Hadanny et al. Hyperbaric oxygen can induce angiogenesis and recover erectile function. Int J Impot Res 2018 (PMID 29773856)
- Full text: Hyperbaric oxygen can induce angiogenesis and recover erectile function (Nature)
- Double-blind, randomized, placebo-controlled trial of HBOT to preserve erectile function after radical prostatectomy. J Urol 2018 (PMID 29031768)
- Sahin et al. The Effect of Hyperbaric Oxygen Therapy on Erectile Functions: A Prospective Clinical Study. Urol Int 2018 (PMID 30089290)
- Hyperbaric oxygen therapy as a treatment for erectile dysfunction: a meta-analysis. Sex Med Rev 2023 (PMID 37952207)
- Eker et al. Comparison of HBOT and daily tadalafil on erectile function. Int Urol Nephrol 2024 (PMID 37910381)
- FDA: Hyperbaric Oxygen Therapy: Get the Facts (Consumer Update on unproven HBOT uses)
- PubMed: hyperbaric oxygen therapy and erectile dysfunction (search)